SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

January 29, 2013 07:00 ET

Implant Sciences to Exhibit TSA-Approved Explosives Trace Detector at AirCargo 2013 Conference

WILMINGTON, MA--(Marketwire - Jan 29, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today the Company will be an exhibitor at AirCargo 2013, a leading tradeshow and conference for the domestic U.S. air cargo industry. Implant Sciences will be exhibiting its Quantum Sniffer™ QS-B220 desktop explosives and drugs trace detector, which received TSA approval for use in air cargo security on January 15, in booth #91.

AirCargo attracts nearly 1,000 industry representatives from the express delivery industries, airlines, air forwarding companies, air freight and expedited trucking companies, logistics providers, courier companies, airport authorities, and the suppliers to these industries. This year's conference will take place between March 10-12 in Las Vegas.

"The timing of this important trade show is very opportune for us. Having just received TSA approval for our QS-B220 for use in air cargo screening, we are in a position to exhibit and take orders from air cargo customers shipping to or from the U.S.," stated Implant Sciences' President and CEO, Glenn D. Bolduc. "Although historically a majority of our sales have been to customers outside of the U.S., with TSA approval, we believe that we will significantly increase sales domestically."

About the Quantum Sniffer™ QS-B220 Desktop Explosives Trace Detector

The TSA approved Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, as well as drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and internal automatic self-calibration, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About the Quantum Sniffer™ QS-H150 Handheld Explosives Trace Detector

The Quantum Sniffer QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 desktop explosives and drugs trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:


    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact